Verification register Bio, Health & Neuro
Living definition
What is Kisunla (donanemab)?
Drug Discovery & Development Bio, Health & Neuro
- As of
- 2026-07-23
- Revision
- 2026-07-26.1
- Method
- v1.3.0
Definition
The term, in context
AI-assisted draft · approved dataset
Kisunla (donanemab) is a monoclonal antibody therapy for early Alzheimer's disease that binds deposited amyloid plaque and promotes its clearance from brain tissue.
Live readiness status
Status as of the current dateline
AI-assisted assembly · derived results
As of 2026-07-23, verified readiness is 57 (claimed 70, reported 65, gap 13) — Strong evidence strength; current signals suggest Proceed with caution.
The readiness fact belongs to the canonical Readiness Verdict for Kisunla (donanemab).
Dataset approval
Human editorial release
pragma.vision editorial — standing authorization (operator dev@soft.house, 2026-07-17)
- Dataset
- 2026-07-26.1
- Hash
- sha256:a5b861157968f418e08e6a08da71c7cfd4c6b23c3955d9d77ad5bcf67b9e2482
- Approved
- 2026-07-26